Inventage Lab Inc. Logo

Inventage Lab Inc.

Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.

389470 | KO

Overview

Corporate Details

ISIN(s):
KR7389470006
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로388번길 24, 101호, 601호, 612호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Inventage Lab Inc. is a clinical-stage biopharmaceutical company that develops advanced drug delivery systems (DDS) for chronic and intractable diseases. The company's core innovation is its proprietary Laminar-FLUIDigm™ platform, which utilizes microfluidics for the research and development of novel pharmaceuticals. Inventage Lab operates two primary technology platforms: IVL-DrugFluidic® for developing and manufacturing microsphere-based long-acting injectables, and IVL-GeneFluidic® for the formulation of Lipid Nanoparticles (LNPs) used in gene therapies. Its therapeutic pipeline focuses on unique-in-class treatments for conditions like Alzheimer's disease and androgenic alopecia, drug re-discovery for autoimmune disorders, and joint development of treatments for HIV and mRNA-based therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-21 00:00
Legal Proceedings Report
소송등의판결ㆍ결정 (신주상장금지 등 가처분-취하)
Korean 5.3 KB
2025-10-21 00:00
Legal Proceedings Report
소송등의판결ㆍ결정 (신주발행무효 확인의 소-취하)
Korean 5.1 KB
2025-10-20 00:00
Legal Proceedings Report
주요사항보고서(소송등의제기)
Korean 6.7 KB
2025-10-20 00:00
Legal Proceedings Report
주요사항보고서(소송등의제기)
Korean 7.3 KB
2025-09-23 00:00
Share Issue/Capital Change
전환청구권행사 (제2회차)
Korean 8.6 KB
2025-09-22 00:00
Share Issue/Capital Change
전환청구권행사 (제2회차)
Korean 8.7 KB
2025-09-10 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (알코올 의존성 및 opioid 의존성 치료제(IVL3004) 및 다발성 경화증 …
Korean 15.3 KB
2025-08-27 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-07-31 00:00
M&A Activity
투자판단관련주요경영사항 (FGF-21기반 mRNA-LNP 대사성 질환치료제 독점적 권리 도입 계약 체결)
Korean 10.9 KB
2025-07-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.1 KB
2025-07-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-07-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.2 KB
2025-07-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB

Automate Your Workflow. Get a real-time feed of all Inventage Lab Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inventage Lab Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inventage Lab Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.